| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.002 | 1 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0017 | 1 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0023 | 1 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | -0.0054 | 1 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.0014 | 1 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.0024 | 1 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.00085 | 1 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.0008 | 1 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.0007 | 1 |